title: The effect of teriparatide to alleviate pain and to prevent vertebral collapse after fresh osteoporotic vertebral fracture.
abstract: Vertebral fracture is often seen in osteoporotic patients. Teriparatide is expected to promote bone union. Therefore, we evaluated the action of vertebral collapse prevention by administering teriparatide to vertebral fracture patients. Thirty-four patients with fresh vertebral fracture (48 vertebrae) participated in this study. They were administered either teriparatide (daily 20 µg/day or weekly 56.5 µg/week) or risedronate (17.5 mg/week): ten patients (20 vertebrae) received teriparatide daily (Daily group), 11 patients (15 vertebrae) received teriparatide weekly (Weekly group), and 13 patients (14 vertebrae) received risedronate (RIS group). We compared some laboratory examination items, visual analogue scale (VAS) of low back pain, vertebral collapse rate and local kyphotic angle, and the cleft frequency. In addition, we evaluated 22 vertebral fracture patients (24 vertebrae) who did not take any osteoporotic medicines (Control group). There was no significant difference in any of the scores at the start of treatment. At 8 and 12 weeks after the initial visit, VAS scores in the Daily and Weekly groups were significantly lower than in the RIS group (p < 0.05). At 8 and 12 weeks, the vertebral collapse rate and local kyphotic angle in the Daily group were significantly lower than in the RIS and Control groups (p < 0.01 and p < 0.05, respectively), and those in the Weekly group were significantly lower than in the Control group (p < 0.05). The cleft frequency in the Daily group was significantly lower than in the RIS group (p < 0.05). Teriparatide is promising for the prevention of vertebral collapse progression after vertebral fracture.
authors.affiliation: Division of Orthopedic Surgery, Nakadori General Hospital, 3-15, Misono-cho, Minami-dori, Akita, 010-8577, Japan. tuchikiti@yahoo.co.jp.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Tsuchie
authors.affiliation: Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
authors.forename: Naohisa
authors.initials: N
authors.lastname: Miyakoshi
authors.affiliation: Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
authors.forename: Yuji
authors.initials: Y
authors.lastname: Kasukawa
authors.affiliation: Ugo Municipal Hospital, 44-5 Otomichi, Nishimonai, Ugo, 012-1131, Japan.
authors.forename: Tomio
authors.initials: T
authors.lastname: Nishi
authors.affiliation: Ugo Municipal Hospital, 44-5 Otomichi, Nishimonai, Ugo, 012-1131, Japan.
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Abe
authors.affiliation: Ugo Municipal Hospital, 44-5 Otomichi, Nishimonai, Ugo, 012-1131, Japan.
authors.forename: Toyohito
authors.initials: T
authors.lastname: Segawa
authors.affiliation: Department of Orthopedic Surgery, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Shimada
mesh_terms: D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D058866:Osteoporotic Fractures / Q000188:drug therapy*; D010146:Pain / Q000188:drug therapy; D016103:Spinal Fractures / Q000188:drug therapy*; D019379:Teriparatide / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D050071:Bone Density Conservation Agents; D019379:Teriparatide
keywords: Osteoporosis; Risedronate; Teriparatide; Vertebral collapse; Vertebral fracture